Compare PTCT & AGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | AGX |
|---|---|---|
| Founded | 1998 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 8.4B |
| IPO Year | 2006 | 1995 |
| Metric | PTCT | AGX |
|---|---|---|
| Price | $72.40 | $608.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | $80.65 | ★ $409.50 |
| AVG Volume (30 Days) | ★ 774.1K | 445.4K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | ★ 264.48 | 58.37 |
| EPS | 7.78 | ★ 9.74 |
| Revenue | $264,734,000.00 | ★ $944,606,000.00 |
| Revenue This Year | N/A | $33.81 |
| Revenue Next Year | $19.02 | $20.97 |
| P/E Ratio | ★ $9.30 | $62.01 |
| Revenue Growth | ★ 36.19 | 8.06 |
| 52 Week Low | $35.95 | $142.97 |
| 52 Week High | $87.50 | $620.00 |
| Indicator | PTCT | AGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 67.49 |
| Support Level | $69.81 | $258.40 |
| Resistance Level | $79.59 | N/A |
| Average True Range (ATR) | 2.25 | 25.86 |
| MACD | 0.47 | 0.16 |
| Stochastic Oscillator | 81.77 | 89.52 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Teledata, out of which Power Services derives the majority of revenue.